Abstract
Trehalose, a chemical chaperone and mTOR-independent autophagy enhancer, has shown promise in models of Huntington’s disease, Parkinson’s disease and tauopathies. In this study, two trehalase analogs, lactulose and melibiose, were examined for their potentials in spinocerebellar ataxia treatment. Using a SCA3 ATXN3/Q75-GFP cell model, we found that the ATXN3/Q75 aggregation was significantly prohibited by lactulose and melibiose because of their abilities to up-regulate autophagy. Meanwhile, lactulose and melibiose reduced reactive oxygen species production in ATXN3/Q75 cells. Both of them further inhibited the ATXN3/Q75 aggregation in neuronally differentiated SH-SY5Y cells. These findings suggest the therapeutic applications of novel trehalose analogs in polyglutamine aggregation-associated neurodegenerative diseases.
Keywords: ATXN3, autophagy, lactulose, melibiose, spinocerebellar ataxia, trehalose.
CNS & Neurological Disorders - Drug Targets
Title:Novel Lactulose and Melibiose Targeting Autophagy to Reduce PolyQ Aggregation in Cell Models of Spinocerebellar Ataxia 3
Volume: 15 Issue: 3
Author(s): Chih-Hsin Lin, Yih-Ru Wu, Jinn-Moon Yang, Wan-Ling Chen, Chih-Ying Chao, I-Cheng Chen, Te-Hsien Lin, Yi-Ci Wu, Kai-Cheng Hsu, Chiung-Mei Chen, Guan-Chiun Lee, Hsiu-Mei Hsieh-Li, Chi-Mei Lee and Guey-Jen Lee-Chen
Affiliation:
Keywords: ATXN3, autophagy, lactulose, melibiose, spinocerebellar ataxia, trehalose.
Abstract: Trehalose, a chemical chaperone and mTOR-independent autophagy enhancer, has shown promise in models of Huntington’s disease, Parkinson’s disease and tauopathies. In this study, two trehalase analogs, lactulose and melibiose, were examined for their potentials in spinocerebellar ataxia treatment. Using a SCA3 ATXN3/Q75-GFP cell model, we found that the ATXN3/Q75 aggregation was significantly prohibited by lactulose and melibiose because of their abilities to up-regulate autophagy. Meanwhile, lactulose and melibiose reduced reactive oxygen species production in ATXN3/Q75 cells. Both of them further inhibited the ATXN3/Q75 aggregation in neuronally differentiated SH-SY5Y cells. These findings suggest the therapeutic applications of novel trehalose analogs in polyglutamine aggregation-associated neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Lin Chih-Hsin, Wu Yih-Ru, Yang Jinn-Moon, Chen Wan-Ling, Chao Chih-Ying, Chen I-Cheng, Lin Te-Hsien, Wu Yi-Ci, Hsu Kai-Cheng, Chen Chiung-Mei, Lee Guan-Chiun, Hsieh-Li Hsiu-Mei, Lee Chi-Mei and Lee-Chen Guey-Jen, Novel Lactulose and Melibiose Targeting Autophagy to Reduce PolyQ Aggregation in Cell Models of Spinocerebellar Ataxia 3, CNS & Neurological Disorders - Drug Targets 2016; 15 (3) . https://dx.doi.org/10.2174/1871527314666150821101522
DOI https://dx.doi.org/10.2174/1871527314666150821101522 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design The Proteasome in Health and Disease
Current Pharmaceutical Design Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Current Pharmaceutical Design Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design Patents Related to Cancer Stem Cell Research
Recent Patents on DNA & Gene Sequences Pharmacodynamics of Memantine: An Update
Current Neuropharmacology ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design Gene Expression Under the Influence: Transcriptional Profiling of Ethanol in the Brain
Current Psychopharmacology Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Nucleic Acid Based Therapeutics for Tumor Therapy
Anti-Cancer Agents in Medicinal Chemistry The Relationship Between Cleft Lip, Maxillary Hypoplasia, Hypoxia and Phenytoin
Current Pharmaceutical Design Xanthones from Mangosteen Extracts as Natural Chemopreventive Agents: Potential Anticancer Drugs
Current Molecular Medicine Collective Roles of Molecular Chaperones in Protein Degradation Pathways Associated with Neurodegenerative Diseases
Current Pharmaceutical Biotechnology N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimer’s Disease, Vascular Dementia and Parkinson’s Disease
Current Alzheimer Research Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies
Current Alzheimer Research Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Solubility Enhancement and Delivery Systems of Curcumin a Herbal Medicine: A Review
Current Drug Delivery Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets
Current Signal Transduction Therapy Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease
Current Pharmaceutical Biotechnology